Nimble Therapeutics

Nimble Therapeutics is a biotechnology company based in Madison, Wisconsin, with an additional R&D site in Philadelphia, Pennsylvania. Founded in 2019, the company specializes in the discovery and development of oral peptide therapeutics aimed at treating immune-mediated diseases. Nimble utilizes proprietary platforms that combine solid-phase peptide synthesis, chemical and structural diversity, advanced assays, machine learning, and computational methods to create innovative therapeutic candidates.

Nimble's lead asset is a preclinical oral peptide IL-23R inhibitor targeting conditions such as psoriasis and inflammatory bowel disease. The company also has other preclinical programs, including a C5 inhibitor for myasthenia gravis and additional IL-23R inhibitors. In December 2024, Nimble was acquired by AbbVie, enhancing its immunology research efforts and integrating its technology and team into AbbVie's broader pipeline. The company has established collaborations with Genentech to further develop peptide therapies across various therapeutic areas.